Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | ATIC | P31939 | 1/20 | 0.67 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.61 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14432590 | 0.85 | KDM4E (0.73) | HSD17B10HPGDKDM4EALDH1A1MEN1 | |
| SCHEMBL2166364 | 0.83 | KDM4E (0.71) | HSD17B10HPGDKDM4EALDH1A1MEN1 | |
| SCHEMBL28184153 | 0.82 | HSD17B10 (0.70) | HSD17B10HPGDKDM4EALDH1A1MEN1 | |
| SCHEMBL5539615 | 0.82 | HSD17B10 (0.88) | HSD17B10HPGDKDM4EALDH1A1MEN1 | |
| SCHEMBL9618861 | 0.82 | HSD17B10 (0.74) | HSD17B10HPGDKDM4EALDH1A1MEN1 | |
| SCHEMBL10448734 | 0.81 | ALDH1A1 (0.69) | HSD17B10HPGDKDM4EALDH1A1MEN1 | |
| SCHEMBL4781635 | 0.81 | ALDH1A1 (0.68) | HSD17B10HPGDKDM4EALDH1A1MEN1 | |
| SCHEMBL317180 | 0.80 | THRB (1.00) | HSD17B10HPGDKDM4EALDH1A1MEN1 | |
| SCHEMBL13656899 | 0.80 | MEN1 (0.66) | HSD17B10HPGDKDM4EALDH1A1MEN1 | |
| SCHEMBL7797719 | 0.80 | MAPT (0.66) | HSD17B10HPGDKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | claimed |
| CN-101175720-A | Novel haloalkyl sulfone substituted compounds useful for the treatment of obesity and diabetes | NOVO NORDISK AS (DK) | 2008-05-07 | — | — | CN | claimed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | claimed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | claimed |
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |
| US-6238842-B1 | SUITABLE FOR USE WITH AN EXPOSURE LIGHT HAVING A WAVELENGTH OF 250 NM OR SHORTER, ESPECIALLY 220 NM OR SHORTER; ACID GENERATING COMPOUND; RESIN HAVING MONOVALENT POLYALICYCLIC GROUPS | FUJI PHOTO FILM CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| US-5532138-A | Method and kits for determining peroxidatively active catalysts | BEHRINGWERKE AG (DE) | 1996-07-02 | — | — | US | disclosed |
| EP-0585116-B1 | 1-Alkoxy-naphthalene-2-carboxamide derivatives with high affinity for the serotonin 5-HT1A receptor | LILLY INDUSTRIES LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| US-5389684-A | Treats disorder of central nervous system | LILLY INDUSTRIES LIMITED (GB) | 1995-02-14 | — | — | US | disclosed |
| EP-0585116-A1 | 1-Alkoxy-naphthalene-2-carboxamide derivatives with high affinity for the serotonin 5-HT1A receptor | LILLY INDUSTRIES LIMITED (GB) | 1994-03-02 | — | — | EP | disclosed |
| US-4885270-A | O-HYDROXY AROMATIC ACID ESTER SENSITIZER, COLOR FORMING LACTONE; THERMAL PRINTING | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1989-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | HSD17B10 15/4885HPGD 2252/4885KDM4E 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.